Article Details

AstraZeneca says ENHERTU achieved 61.6% progression-free survival rate in study

Retrieved on: 2024-09-13 14:11:35

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca says ENHERTU achieved 61.6% progression-free survival rate in study. View article details on hiswai:

Summary

The article details the significant efficacy of ENHERTU, an antibody-drug conjugate co-developed by AstraZeneca and Daiichi Sankyo, in treating HER2-positive metastatic breast cancer, especially for patients with brain metastases. 'Natural medicine' is highlighted by the results being published in *Nature Medicine*.

Article found on: www.tipranks.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up